Updated
NRX PharmaceuticalsNRXP · Healthcare
$2.38+4.85%
Market cap$103M
IndustryBiotechnology
NRX Pharmaceuticals (NRXP) Financial statements
NRX Pharmaceuticals reported revenue of $1M in fiscal 2025.
Key figures
Net income was -$29M. The diluted share count rose 8086% over the period (dilution).
- Revenue, FY2025
- $1M
- Net income
- -$29M+13.9% on 2024
- Operating margin
- -1324.4%
- Free cash flow
- —
Revenue and free cash flow
Fiscal years, from NRX Pharmaceuticals's 10-K filings.
NRX Pharmaceuticals revenue and free cash flow
FY2018–FY2025NRXPRevenue$1MNRXPFree cash flow-$11M
Financial statements
Fiscal 2018–2025.
NRX Pharmaceuticals income statement, fiscal 2018–2025
| USD | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $0 | $0 | $1M |
| Cost of revenue | — | — | — | — | — | — | $0 | $505,000 |
| Gross profit | — | — | — | — | — | — | $0 | $720,000 |
| Research and development | — | — | $11M | $20M | $17M | $13M | $6M | $4M |
| Selling, general and admin | — | — | $11M | $75M | $27M | $14M | $14M | $13M |
| Operating income | -$1M | -$713,187 | -$51M | -$116M | -$44M | -$28M | -$19M | -$16M |
| Interest expense | — | — | $56,000 | $18,000 | — | $120,000 | $230,000 | $671,000 |
| Pre-tax income | $82,412 | $492,633 | -$52M | -$93M | -$40M | -$30M | -$25M | -$29M |
| Income tax | $16,311 | $84,206 | $17,841 | — | — | $0 | $0 | $0 |
| Net income | $66,101 | $408,427 | -$52M | -$93M | -$40M | -$30M | -$25M | -$29M |
| EPS (diluted) | -$2.90 | -$1.10 | -$15.10 | -$19.80 | -$6.00 | -$3.98 | -$2.36 | -$1.34 |
| Diluted shares | 0M | 0M | 3M | 5M | 7M | 8M | 11M | 21M |
| Gross margin | — | — | — | — | — | — | — | 58.8% |
| Operating margin | — | — | — | — | — | — | — | -1324.4% |
| Net margin | — | — | — | — | — | — | — | -2336.5% |
NRX Pharmaceuticals balance sheet, fiscal 2018–2025
| USD | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $11,079 | $6 | $2M | $28M | $20M | $5M | $1M | $8M |
| Receivables | — | — | $831,000 | — | — | — | $0 | $161,000 |
| Total current assets | $30,193 | $69,489 | $3M | $33M | $26M | $7M | $3M | $9M |
| Property, plant and equipment | — | — | — | — | — | — | $10,000 | $63,000 |
| Goodwill | — | — | — | — | — | — | $0 | $2M |
| Total assets | $71M | $32M | $3M | $33M | $26M | $7M | $4M | $13M |
| Total current liabilities | $567,410 | $622,441 | $46M | $12M | $16M | $19M | $22M | $29M |
| Long-term debt | $690,000 | $2M | — | — | $3M | $0 | $5M | $0 |
| Total liabilities | $1M | $3M | $47M | $12M | $18M | $19M | $27M | $29M |
| Shareholders' equity | $5M | -$5M | -$44M | $21M | $7M | -$12M | -$23M | -$16M |
| Net debt | $678,921 | $3M | -$49,111 | -$27M | -$10M | $5M | $5M | -$8M |
NRX Pharmaceuticals cash flow, fiscal 2018–2025
| USD | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$473,187 | -$792,731 | -$2M | -$38M | -$40M | -$22M | -$11M | -$14M |
| Capital spending | — | — | $2,000 | $7,000 | $10,000 | $3,000 | $0 | — |
| Free cash flow | — | — | -$2M | -$38M | -$40M | -$22M | -$11M | — |
| Stock-based compensation | — | — | $730,000 | $8M | $4M | $387,000 | $486,000 | $228,000 |
How NRX Pharmaceuticals compares
NRX Pharmaceuticals's operating margin is higher than 11% of Healthcare companies and 4% of the 2,820 companies with an operating margin figure.
| Higher than | Healthcare | All stocks |
|---|---|---|
| Operating margin | 11% | 4% |
| Net margin | 10% | 3% |
| Gross margin | 28% | 57% |
Questions about NRX Pharmaceuticals
What was NRX Pharmaceuticals's revenue in 2025?
$1M in fiscal 2025, from its 10-K filing.
From NRX Pharmaceuticals's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.